Argo

Argo Biopharma was founded in 2021 and is committed to developing a new generation of RNAi drugs. The company is currently registered and located in Jiading District, Shanghai. In the future, it will rely on a world-leading drug design and development platform to provide better treatment options for patients worldwide. Argo Biopharma was established by several scientists with deep experience in RNAi drug development who returned to China. The team has extensive experience in all aspects of RNAi drug development, including bioinformatics and nucleic acid sequence design, chemical modification, GalNAc conjugation technology, extrahepatic delivery technology development, and oligonucleotide CMC. The company’s team will use next-generation drug design processes and development strategies to expand the indications for RNAi therapies and fill the gap in this field in China.